Pervasive Intronic Polyadenylation Serves as a Potential Source of Cancer Neoantigens - 2022

Xi Ren1,†, Bin Zhang1,†, Jia Li1,†, Thamizhanban Manoharan3,4, Beijia Liu3, Yang Yang Song1, Shu Ye Tian5, Kar Tong Tan1,6, Ling Wen Ding7, Ying Li1, Omer An1, Ming Li2, Chan Shuo Wu1, Yang Liu1,8, Boon Heng Teo9,10, Sze Jing Tang1, Jinhua Lu9,10, Yu Hui Hu5, Wei Chen5, Leilei Chen1,11, Gloryn Chia3,4,*, Henry Yang1,2,

Abstract

Tumor-specific neoantigens have emerged as a promising source for cancer immunotherapy. These tumor-specific neoantigens could arise from somatic mutations, aberrant splicing and RNA editing. Since intronic polyadenylation has similar potential as mutations to generate tumor-specific transcripts and peptides, it may serve as another neoantigen source, which has not been explored. We developed a novel computational pipeline for identification of tumor-specific transcripts and their translated neoantigens derived from intronic polyadenylation. Applying it to RNA-seq data from 5,654 tumor samples of various cancers and 11,000 + normal samples of different tissues, we observed widespread tumor-specific intronic polyadenylated transcripts and their corresponding neoantigens. In addition, we also discovered complementary effects of neoantigens derived from different sources, identified neoantigens arising from recurrent intronic polyadenylated transcripts, and validated their immunogenicity. Here, we have demonstrated that we were able to identify and predict neoantigens from intronic polyadenylated transcripts using RNA sequencing data, hence, allowing us to explore such neoantigens as potential candidates for cancer immunotherapy.

Read More